Acute hepatitis E virus infection causing acute liver failure requiring living-donor liver transplantation in a non-pregnant immunocompetent woman by Li, WS & Chok, KSH
Title
Acute hepatitis E virus infection causing acute liver failure
requiring living-donor liver transplantation in a non-pregnant
immunocompetent woman
Author(s) Li, WS; Chok, KSH
Citation Transplant Infectious Disease, 2017, v. 19 n. 3, p. e12699
Issued Date 2017
URL http://hdl.handle.net/10722/242875
Rights
This is the accepted version of the following article: Transplant
Infectious Disease, 2017, v. 19 n. 3, p. e12699, which has been
published in final form at
https://onlinelibrary.wiley.com/doi/abs/10.1111/tid.12699; This
work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1111/tid.12699 
This article is protected by copyright. All rights reserved. 
Received Date : 13-Sep-2016 
Revised Date   : 30-Nov-2016 
Accepted Date : 30-Dec-2016 
Article type      : Case Report 
 
CASE REPORT 
Acute hepatitis E virus infection causing acute liver failure requiring living-
donor liver transplantation in a non-pregnant immunocompetent woman 
 
Wai Sum Li 1 and Kenneth Chok2 
1Queen Mary Hospital,  Hong Kong, China 
2Department of Surgery, The University of Hong Kong, Hong Kong, China 
 
Correspondence: 
Wai Sum Li 
Queen Mary Hospital 
Hong Kong, China 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Email: irisli.irisli.irisli@gmail.com 
Short title: LI & CHOK 
 
Abstract:  
We report a rare case of acute liver failure from acute hepatitis E virus (HEV) in a non-
pregnant woman without comorbidities who survived after liver transplantation. The 
source was likely consumption of partially cooked pig liver. HEV genotype 3 is the 
second most common genotype causing acute hepatitis E in developed countries. 
Fulminant hepatitis E rarely occurs without a risk factor, as in our patient. Vigilant 
monitoring for chronic hepatitis E in post-transplant immunocompromised patients is 
needed. 
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1 INTRODUCTION 
Hepatitis E virus (HEV) is a small, 27-34 nm in diameter, non-enveloped single-stranded 
RNA virus, and the only member of the genus Orthohepevirus, in the family Hepeviridae. 
The genome size is about 7.2-kilobases.1,2  Human HEV belongs to the mammalian HEV 
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species, with one serotype but four phylogenetically distinct genotypes. Genotype 1 
includes strains from Asia and Africa, and genotypes 3 and 4 include human and swine 
HEV strains from industrialized countries and Asia, especially China.3,4   
 Human HEV infection clinically causes acute hepatitis E, and chronic hepatitis E in 
immunocompromised patients. The transmission route is primarily fecal-oral, most 
commonly water-borne in highly endemic areas of the Indian subcontinent, China, 
Southeast and Central Asia, the Middle East, and northern and western parts of Africa, 
where outbreak and sporadic cases of hepatitis E have been related to HEV genotypes 1 
or 2.3-5 Zoonotic transmission of HEV genotypes 3 and 4 in low endemic areas from 
animal reservoirs was suggested based on detection of HEV genomic material in sera, 
feces, and liver meat from mammalian animals, especially pigs and deer, and the 
phylogenetically close relationship among HEV of animal and human cases. 3-5  Other 
reported transmission routes include blood-borne through contaminated blood and 
blood products, maternal-to-child vertical transmission, and direct contact with HEV-
infected animals.6  
 
2 CASE REPORT  
A 46-year-old woman presented to a regional hospital of Hong Kong (HK) for 2-day 
epigastric pain, yellowish skin discoloration, tea-colored urine, and unremarkable 
medical, allergic, travel, and drug history. She had consumed partially cooked pig liver in 
congee within 2 weeks prior to admission. She did not smoke or drink. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Physical examination revealed temperature 37.4°C,  jaundice, and hepatomegaly 
without stigmata of chronic liver disease or hemodynamic instability. Initial laboratory 
investigations are shown in Table 1. Empirical intravenous antibiotics were given as 
treatment for biliary sepsis.  
 She subsequently developed hepatic encephalopathy and flapping tremor. She 
was transferred to the intensive care unit of a tertiary hospital with the only liver 
transplantation (LT) center in HK, for management of acute liver failure (ALF) and LT 
workup (Tables 1 and 2). The ammonium and lactate peaked at 229 µmol/L and >24 
mmol/L respectively. Ultrasonography and computed tomography of abdomen were 
unremarkable. 
 Her liver function test results deteriorated further (Table 2), and she underwent 
total hepatectomy and living-donor right lobe LT for life saving. Her serum was tested in 
the regional reference laboratory and was positive for anti-HEV immunoglobulin-G (IgG) 
(MP Diagnostics HEV IgG ELISA) and immunoglobulin-M (IgM) (MP Diagnostics HEV IgM 
ELISA), and reverse-transcription polymerase chain reaction targeting ORF2 region, and 
sequencing and phylogenetic analysis revealed HEV-genotype 3. Post LT, she received 
mycophenolate mofetil and tacrolimus, and her liver function tests gradually improved 
(Table 2).  
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3 DISCUSSION 
This is the first case report, to our knowledge, of HEV genotype 3-associated ALF in an 
immunocompetent patient, successfully treated with living-donor LT in HK, where 
endemicity is low for HEV. Hepatitis E in immunocompetent patients is generally self-
limiting, especially for those without risk factors for ALF including chronic drinking 
history, chronic liver disease, and pregnancy, and is managed supportively.4,7 The likely 
source of her infection was consumption of partially cooked pig liver in congee. HEV 
genotypes 3 and 4 have been recovered from humans, pigs, and deer.3,4 Genotype 3 is 
the second most common genotype for hepatitis E in HK, following genotype 4, which 
constitutes >94%.3,4,7,8 
 Our patient’s obtunded mental state pre-LT was related to hepatic 
encephalopathy rather than neurological extrahepatic manifestation of hepatitis E 
(Table 3).4 The reason for her ALF was not precisely known. Immune response, rather 
than viral damage to hepatocytes, was suggested clinically for her hepatitis E including 
ALF.9 For host factors, her initial total lymphocyte count of 1300 cells/µL might predict 
CD4 lymphocyte count to 350 cells/µL.10-12 This finding might be part of HEV clinical 
manifestation, as 7.5% of autochthonous hepatitis E patients had lymphopenia.13 The 
peripheral lymphocytes recruitment to liver, with the characteristic lymphocytic 
inflammatory infiltration, predominantly CD8, CD3, and CD4 lymphocytes, in expanded 
portal tract in acute hepatitis E patients, might explain her peripheral lymphopenia.6,14 
Her subsequent elevated total lymphocyte count likely resulted from host cellular 
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immune response. The speculated expanded natural killer cell population may produce 
elevated levels of interferon-γ and contribute to hepatocyte death.9 CD8 lymphocyte 
proportion was higher in deceased liver of HEV-associated ALF than other hepatotropic 
viruses.9  Her human immunodeficiency virus (HIV) test was negative and profiles of 
immunoglobulin levels were within range, with no known immunodeficiency, and no 
information on human leukocyte antigen typing, which was a required workup for bone 
marrow transplantation, but not for LT, and without any conditioning therapy pre-LT.  
 For virus factors, patients infected with HEV genotype 3 or 4 with isolated 
synonymous substitution of U at nucleotide (nt) 3148 (U3148) in HEV RNA helicase 
domain or with co-occurrence of substitution of C at nt 5907 (C5907) within ORF2, were 
associated with ALF.15,16 The lower value of lowest prothrombin activity was significantly 
lower, and total bilirubin and alanine aminotransferase (ALT) higher, in these 
patients.15,16 
The lack of viral load (VL) quantitation and full genome sequencing in our patient 
are limitations of our report. This was technically limited by their unavailability at 
hospital service and reference laboratories. Our patient’s initial calculated prothrombin 
activity (37.3%) 17 was even lower, while total bilirubin and ALT levels were even higher 
than those with U3148 ± C5907 in HEV.15,16  Consistently, her prothrombin times were 
lower and her total bilirubin was higher than those resulting from HEV with 
nonsynonymous mutation identified in RNA-dependent RNA polymerase region causing 
an amino acid change from cysteine to tryptophan at position 1483 (C1483W), or 
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asparagine to threonine at 1530 (N1530T) respectively, which was significantly 
associated with abnormal prothrombin time, high VL, and mortality.18  
 Chronic HEV infections have developed in HEV-infected immunocompromised 
patients and were of genotype 3, in up to 60% in infected solid organ transplant 
recipients, less common in HIV or hematological malignancies patients,4,19 and very low-
risk in stem cell transplant recipients. 19 No HEV reactivation has occurred in our patient 
so far at 4 years post LT (at the time of this report submission). Unlike those reported 
who developed hepatitis E infection during post-transplant and/or with 
immunocompromised status, 4,20,21 our patient developed acute hepatitis E pre-LT, and 
had LT in 4 days. Even though HEV persists in human liver or in macrophages 19,21,22 or 
extrahepatic sites as in animal models, 21 her liver, with HEV in hepatocytes and Kupffer 
cells, had been removed by total hepatectomy, which reduced her HEV VL before 
receipt of donor liver and immunosuppression. Replication of HEV in peripheral blood 
mononuclear cells of infected patients was found to be unlikely.19 Her post-LT 
immunosuppressant, mycophenolate mofetil, which is a prodrug of mycophenolic acid 
that in-vitro inhibits HEV replication, may be associated with HEV clearance,21 despite 
the fact that tacrolimus concomitantly stimulates HEV replication in vitro, and was the 
main predictor for chronic hepatitis E in solid organ transplant recipients.20-22  
 Dose reduction of immunosuppressants remains the initial management of 
chronic hepatitis E in immunocompromised patients for clearance of HEV viremia, 
followed by antivirals for those non-responders with persistent viremia.21,23 A 3-month  
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course of ribavirin (RBV) or pegylated interferon-α-2a, either monotherapy or in 
combination, has been reported as effective treatment for severe HEV infection in non-
immunocompromised or immunocompromised patient.21,23-27 In all, 78% of infected 
transplant recipients achieved sustained virological response after RBV monotherapy.25-
27  A second prolonged course was needed for treating recurrence of HEV viremia.27  
Sofosbuvir inhibits HEV genotype 3 replication in vitro, and with additive inhibitory 
effect when combined with RBV.21,28 Further clinical studies are needed to investigate 
RBV and sofosbuvir combination for treating chronic hepatitis E and HEV superinfection 
in immunocompromised patients, and on different genotypes.  
 Further follow-up for surveillance and detection of chronic hepatitis E symptoms 
and signs, virologically and radiologically, are needed for prompt diagnosis of chronic 
hepatitis E in our patient status post LT. 4 The hospital laboratory should develop new 
tests to cope with patient service needs accordingly. Further research may answer the 
differential transmission mode and virulence among genotypes, and genetic relatedness 
between human and swine HEV.3 This is an unusual autochthonous case of HEV 
genotype 3-associated ALF in an immunocompetent woman. LT is a life-saving option for 
patients with ALF caused by HEV who fulfill transplantation criteria.    
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TABLE 1 Hematological and biochemical results of our patient with acute hepatitis E  
 Admis
sion 
to 
region
al 
hospit
al 
Refer
ence 
range 
Admis
sion 
to 
tertia
ry 
hospit
al 
Day of 
transplan
tation 
1 month 
post 
transplan
tation 
Day 
of 
hospi
tal 
disch
arge 
2 months 
post 
transplan
tation on 
follow up 
Refer
ence 
range 
Complete 
blood picture  
     
White blood 
cells (WBC, 
x109/L) 
7.8 3.7-
9.3 
25.85 28.87 8.58 6.33 5.27 3.89-
9.93 
Neutrophil 
(x109/L) 
5.1 1.8-
6.2 
20.68 22.92 6.85 4.87 4.24 2.01-
7.42 
Lymphocyte (x 
109/L) 
1.3 1.0-
3.2 
2.33 5.06 0.77 0.75 0.57 1.06-
3.61 
 Monocyte 
(x109/L) 
0.9 0.2-
0.7 
1.29 2.97 0.65 0.51 0.35 0.18-
0.65 
Hemoglobin 
(Hb, g/dL) 
10.3 11.5-
15.4 
8.7 5.6 8.9 8.8 9.6 11.5-
14.8 
Platelet (Plt, 
x109/L) 
100 8.1-
11.5 
114 82 342 257 323 162-
341 
Clotting 
profile 
     
PT (sec) 18.3 10.1-
12.4 
 37.8 19.1 18.7 12.9  
INR 1.6   3.3 1.8 1.7 1.2  
APTT (sec) 51.9 25.1- 
35.5 
 49.0 34.4 33.7 29.4  
      
Renal function      
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test 
Sodium 
(mmol/L) 
139 136-
145 
 137 137 137 140 136-
148 
Potassium (K, 
mmol/L) 
3.8 3.5-
5.1 
 4.1 4.2 4.2 4.7 3.6-
5.0 
Urea (mmol/L) 4.2 <8.3  12.7 14.5 7.0 4.1 2.8-
6.7 
Creatinine 
(umol/L) 
48 44-80  99 103 102 110 49-82
Ammonia 
(μmol/L) 
ND ND  139 229 <9 ND <33
Liver function 
test 
     
Total protein 
(g/L) 
61 64-83  75 77 62 61 67-87
Albumin ( g/L) 29 35-52  26 30 32 30 39-50
Globulin (g/L) 32   49 47 30 31 26-40
Bilirubin, total 
(μmol/L) 
331 <17  780 854 30 12 4-23
Alkaline 
phosphatase 
(U/L) 
159 35-
104 
 152 138 134 177 32-93
Alanine 
transaminase 
(U/L) 
3306 <33  >3000 >3000 68 111 7-36
Aspartate 
transaminase 
(U/L) 
   >3000 >3000 40 56 14-30
ND, not done; PT, prothrombin time; INR, international normalized ratio; APTT, activated partial 
thromboplastin time. 
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TABLE 2 Results of investigation performed for acute liver failure and transplant  
workup in our patient.  
Tests performed  Results (reference range)
HBsAg  Negative 
Anti-HBs <10
Anti-HBc (Total) Negative
Hepatitis B DNA viral load  <10 IU/mL
Anti-HAV Ab (total) Positive 
Anti-HAV IgM Negative 
Anti-HEV (total) Positive 
Anti-HEV IgM  Positive 
Anti-HIV-1 Negative 
Antibody titer  
    CMV IgG  Positive 
    EBV-VCA polyvalent  640
   HSV  Anti-complementary reaction 
   Hantavirus polyvalent <40
   Widal test (TO, TH, AH, BH, CH) < 1:50
Leptospira IgM  Negative 
Bacterial culture  
Blood, sputum & urine  No growth 
Immunoglobulin levels 
IgG 21.80 (7.00-16.00) g/L 
IgA 5.15 (0.70-4.00) g/L
IgM 2.82 (0.40- 2.30) g/L
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Autoimmune markers
C3  46 (76-150) mg/dL
C4 14 (9-35) mg/dL
ANA titer Negative 
Anti-ENA screen  Negative
Anti-smooth muscle Ab Negative
Anti-mitochondrial Ab  Negative
Tumor markers  
Alpha-fetoprotein 1.0 (≤ 5.8) IU/mL
CA19-9 8.2 (<37) U/mL
Carcinoembroyonic antigen  1.1 (<5) ng/mL
      CA15.3 20 (<23) U/mL
Copper  16 (11.0-25.0) μmol/L
Ceruloplasmin 0.47 (0.19-0.40) g/L
 
HBsAg,  hepatitis B surface antigen; HBs, hepatitis B surface; HBc, hepatitis B core; HAV Ab, 
hepatitis A virus antibody; IgM, immunoglobulin M; HEV, hepatitis E virus; HIV, human 
immunodeficiency virus; CMV, cytomegalovirus; IgG, immunoglobulin G; EBV-VCA, Epstein-Barr 
virus viral capsid antigen; HSV, herpes simplex virus; IgA, immunoglobulin A; ANA, anti-nuclear 
antibody; ENA, extractable nuclear antigens. 
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TABLE 3 Extrahepatic manifestations of hepatitis E 
Acute pancreatitis 
Hematological manifestations 
    Thrombocytopenia
    Hemolysis  
    Hemolysis secondary to G6PD deficiency
    Immune hemolysis
Autoimmune phenomena 
    Membranous glomerulonephritis 
    Henoch-Schönlein purpura 
Neurological syndromes  
    Guillian-Barré syndrome 
    Meningoencephalitis
    Pseudotumor cerebri
    Nerve palsies: oculomotor nerve, facial nerve
    Bilateral pyramidal syndrome 
    Peripheral neuropathy 
 
 
 
 
 
 
